Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy or chemotherapy for resectable locally advanced gastric/gastroesophageal junction adenocarcinoma
ChiCTR2400092029Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Pathological complete response rate. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400092029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092029.